Clinical Trial

TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-26.
Status change: Not Yet Recruiting → Recruiting 2025-02-20
Trial Details
NCT Number NCT06484816
Lead Sponsor Shenzhen TargetRx Co., Ltd.
Collaborators: Sir Run Run Shaw Hospital
Conditions Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
Enrollment 90 participants
Start Date 2024-07-08
Primary Completion 2027-02 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-02-24